The medicinal cannabis product, which is a high THC (tetrahydrocannabinol) flower, has been developed through an extensive research and development programme by Cann Group, Rua's Australian strategic manufacturing, supply and technical services partner.
Nimbus founder and managing director Linus Weber said in Germany, medicinal dried-cannabis flower was prescribed mainly for pain patients.
“At its launch, we believe Rua's flower will be one of the highest THC dried-flower medicines on the market, which will give Rua a significant competitive advantage.
“Through its partnership with Cann Group and with Nimbus as a distribution partner, Rua is well positioned to provide German patients with sustainable access to its product for many years to come.”
Rua chief executive Rob Mitchell said the European medicinal cannabis market was estimated to be worth $3.82 billion by 2026.
“The acquisition of Zalm Therapeutics has enabled us to advance the securing of supply agreements in other emerging, high growth markets, including the Czech Republic, Poland and the United Kingdom.
“The global commercial opportunities open to Rua are compelling and underpinned by our ability to export high-value medicinal cannabis at scale and pace as a result of the partnership we now have with Cann Group and the scale afforded by their Mildura facility,” he said.
Cann's new $120m cultivation and processing facility at Mildura is considered one of the largest and most advanced in Australasia. The first stage of its construction is now operational and capable of producing 12,500 kilograms of dried cannabis flower per year.
When complete, capacity at the 13.5-hectare facility will grow up to 70,000 kilograms.
In a capital-light strategy, Gisborne-based Rua is leveraging this scale to punch above its weight and deliver a range of medicinal cannabis products to multiple export markets in record time.
Rua will announce further expansion plans later in the year as the company finalises distribution agreements across Europe.
